-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GZarlIBAcLn2sIdTRI35oSjKCME3m9amsOyGorJZgQlvnwix2tOJQFGjxiHfPxmY
 anWSPqWsk2mdEyrcFLOUlA==

<SEC-DOCUMENT>0001193125-07-150165.txt : 20070705
<SEC-HEADER>0001193125-07-150165.hdr.sgml : 20070704
<ACCEPTANCE-DATETIME>20070705172948
ACCESSION NUMBER:		0001193125-07-150165
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20070705
DATE AS OF CHANGE:		20070705
EFFECTIVENESS DATE:		20070705

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRYO CELL INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000862692
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SERVICES, NEC [8900]
		IRS NUMBER:				223023093
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23386
		FILM NUMBER:		07965707

	BUSINESS ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
		BUSINESS PHONE:		7277230333

	MAIL ADDRESS:	
		STREET 1:		3165 MCMULLEN BOOTH RD
		STREET 2:		BLDG. B
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33761
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ddefa14a.htm
<DESCRIPTION>PROXY
<TEXT>
<HTML><HEAD>
<TITLE>Proxy</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>(RULE 14A-101)
</B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Proxy Statement Pursuant to Section 14(a) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by the Registrant: <FONT FACE="WINGDINGS">&#120;</FONT>
&nbsp;&nbsp;Filed by a Party other than the Registrant: </FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Preliminary Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B> </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Proxy Statement </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Additional Materials </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CRYO-CELL INTERNATIONAL, INC. </B></FONT></P><HR SIZE="1" NOSHADE COLOR="#000000"
ALIGN="left"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate
box): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#120;</FONT>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee paid previously with preliminary materials. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the form or schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount previously paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, schedule or registration statement no.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="92%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g81558img1.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TWO LEADING INDEPENDENT PROXY ADVISORY FIRMS, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ISS AND GLASS LEWIS, BOTH RECOMMEND THAT CRYO-CELL SHAREHOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>VOTE
&#147;FOR&#148; ALL MANAGEMENT NOMINEES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">July&nbsp;5, 2007 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Dear Fellow Cryo-Cell Shareholder: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Cryo-Cell&#146;s Annual Meeting of Shareholders is less than two weeks away. As you make your
final determination regarding your very important vote in the election of directors, we strongly urge you to follow the recommendations of the two leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass
Lewis&nbsp;&amp; Co. and vote your shares FOR the election of management&#146;s nominees on the <B>WHITE</B> proxy card. <B>Please sign, date and return the company&#146;s WHITE proxy card today, or vote by internet or phone by following the
instructions on the enclosed WHITE proxy card.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We are gratified that both ISS and Glass Lewis recommended that Cryo-Cell shareholders
vote for all of management&#146;s director nominees at the July&nbsp;16, 2007 Annual Meeting. ISS and Glass Lewis are widely recognized as the nation&#146;s two leading independent proxy voting and corporate governance advisory firms. Their analyses
and recommendations are relied upon by hundreds of major institutional investment firms, mutual funds and fiduciaries throughout the United States. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>TO FOLLOW THE RECOMMENDATIONS OF ISS AND GLASS LEWIS, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>VOTE &#147;FOR&#148; MANAGEMENT&#146;S DIRECTOR NOMINEES ON
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE WHITE PROXY CARD TODAY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">In recommending that Cryo-Cell shareholders vote FOR the incumbent Cryo-Cell directors over the slate presented by the Portnoy Group, ISS stated that*: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
FACE="Times New Roman" SIZE="2">Our review of the stock performance for Cryo-Cell, VIAC [ViaCell] and CBAI [Cord Blood America] since April 2005 (when FDA introduced new regulatory standards) indicates comparable performance. Additionally,
Cryo-Cell&#146;s stock price outperformed both its peers over a 2 year period&#133; . </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">. . .The decline in CCEL&#146;s margins have been in
line with that of its peers. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">. . . .The dissident . . . did not present any specific, detailed plan for the company. More importantly, the
dissident did not have any specific strategic recommendations for the company. As noted above, ISS prefers dissidents seeking board control, to present a detailed plan for the company, which could then be compared with that of the management&#146;s
current plan. In this case, the management seems to have a distinct plan, which is to diversify by introducing the new MPSC service. Although it is difficult for ISS to ascertain the future success of management&#146;s strategy, we note the market
seems to have responded positively to management&#146;s initiatives.&nbsp;For instance, Cryo-Cell&#146;s stock price is up 21.7% since announcement of its 1Q FY2007 result on April&nbsp;16, 2007. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><U>ISS Recommendation*: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Further, ISS
believes that management&#146;s plans regarding the direction of the company are much more substantive than those presented by the dissident. As such, ISS recommends that shareholders vote FOR the management nominees on the WHITE proxy card.</I></B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="8%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>*</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>Permission to use quotations was neither sought nor obtained.</I> </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In addition to the ISS report, Glass Lewis stated that*: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">In our view, the Company has performed well under its current leadership. We note that total revenue has grown considerably since fiscal year 2003. More
recently, while SG&amp;A expense as a percentage of sales has increased, the Company&#146;s margin appears in line with that of Viacell Inc., the Company&#146;s primary publicly traded competitor. </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">In light of Cryo-Cell&#146;s financial performance over the past several years, we believe the Dissidents&#146; stated recommendations (to dramatically
reduce SG&amp;A expenses, redirect marketing resources toward doctors&#146; offices, consider a share repurchase program, and cut directors&#146; fees by 50%) do not constitute a substantive plan for improvement. Moreover, we believe that the
Portnoy Group&#146;s demand for control of the Company&#146;s board appears out of line to the Dissidents&#146; ownership of only 13% of the Company&#146;s outstanding common stock. In our view, any dissident shareholder seeking to take over a board
should pay a premium for the privilege through a buyout offer to shareholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><U>Glass Lewis Recommendation*: </U></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2"><B><I></I></B><B><I>Given these considerations, we recommend that shareholders should support management&#146;s nominees. Accordingly, we recommend that
shareholders vote FOR all nominees on the</I></B> <B><I>Company&#146;s <U>WHITE </U>proxy card</I></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We believe that the Portnoy Group
has <B><U>not</U></B> presented Cryo-Cell shareholders with any good reasons to support its unqualified nominees. Your Board&#146;s nominees are highly qualified directors who will continue to serve the interests of all shareholders. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We urge you to show your support for your Board of Directors by signing, dating and returning the enclosed <B>WHITE</B> proxy card today or by following
the instructions for voting by telephone or internet on the enclosed proxy card. Please <B>DO NOT </B>sign or return any gold proxy card sent to you by the Portnoy Group. If you have any questions or need any assistance voting your shares, do not
hesitate to contact Georgeson Inc., who is assisting us in this matter, toll free at (888)&nbsp;605-7511. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">We appreciate your continued
support. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On behalf of your Board of Directors, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">/s/ Mercedes
Walton </FONT></P><HR WIDTH="33%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Mercedes Walton </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Chairman&nbsp;&amp; Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>YOUR VOTE IS IMPORTANT </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">To vote <B>FOR</B> your Company&#146;s nominees, you <B>MUST</B> execute a <B>WHITE</B> proxy card. </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The Board of Directors urges you to <B>DISCARD</B> any gold proxy cards that you may have received from the Portnoy Group. A &#147;WITHHOLD AUTHORITY&#148; vote on the Portnoy
Group&#146;s gold proxy card is <B>NOT</B> a vote for the Board&#146;s nominees. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If you have voted on a gold proxy card but wish to support your Company&#146;s nominees, please sign, date and mail the enclosed <B>WHITE</B> proxy card in the postage-paid envelope
provided as soon as possible. You can also vote by internet or telephone by following the instructions on the WHITE proxy card. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Remember &#150; <B>ONLY YOUR LATEST DATED PROXY WILL DETERMINE HOW YOUR SHARES ARE TO BE VOTED AT THE MEETING.</B> </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If any of your shares are held in the name of a bank, broker or other nominee, please contact the party responsible for your account and direct them to vote your shares <B>FOR</B>
your Company&#146;s nominees on the <B>WHITE</B> proxy card. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">If you have any questions or need assistance in voting your
shares, please contact our proxy solicitor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g81558img2.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">17 State Street, 10</FONT><FONT FACE="Times New Roman"
SIZE="1" COLOR="#000000"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">New York, NY 10004 </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Banks and Brokers (212)&nbsp;440-9800 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2">Shareholders Call Toll Free (888)&nbsp;605-7511 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g81558img1.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INSTITUTIONAL SHAREHOLDER SERVICES, INC. (ISS) RECOMMENDS </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THAT CRYO-CELL SHAREHOLDERS VOTE <U>FOR</U> ALL MANAGEMENT NOMINEES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B><I>&#147;ISS Believes That Management&#146;s Plans Regarding the Direction of the Company Are Much More </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Substantive Than Those Presented By the Dissident&#148; </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Oldsmar, Fla. &#150; July&nbsp;5, 2007 &#150; Cryo-Cell International
Inc. (OTC Bulletin Board: CCEL),</B> announced today that Institutional Shareholder Services. Inc. (ISS) one of the nation&#146;s leading independent proxy advisory firms, recommended that Cryo-Cell shareholders vote unanimously <B>FOR </B>all
Cryo-Cell nominees on the Company&#146;s <B>WHITE </B>proxy card at the Company&#146;s July&nbsp;16, 2007 Annual Meeting, citing their independent view that management&#146;s plans for the Company&#146;s future are &#147;much more substantive&#148;
than those of the dissident Portnoy group. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;We are gratified that both ISS and Glass Lewis recommend that Cryo-Cell shareholders vote for all of
management&#146;s director nominees at the July&nbsp;16, 2007 Annual Meeting,&#148; said Mercedes Walton, Cryo-Cell&#146;s Chairman and CEO. &#147;ISS and Glass Lewis are widely recognized as the nation&#146;s two leading independent proxy voting
and corporate governance advisory firms. Their analyses and recommendations are relied upon by hundreds of major institutional investment firms, mutual funds and fiduciaries throughout the United States.&#148; </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In recommending that Cryo-Cell shareholders vote <B>FOR</B> Cryo-Cell&#146;s incumbent directors and AGAINST the nominees of David Portnoy and his associates, the ISS
report states*: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>&#147;Our review of the stock performance for Cryo-Cell, VIAC [ViaCell] and CBAI [Cord Blood America] since April 2005 (when FDA
introduced new regulatory standards) indicates comparable performance. Additionally, Cryo-Cell&#146;s stock price outperformed both its peers over a 2 year period&#133; .&#148; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><I>. . . .&#147;The decline in CCEL&#146;s margins have been in line with that of its peers. . . .&#148; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>&#147;. .
.. The dissident . . . did not present any specific, detailed plan for the company. More importantly, the dissident did not have any specific strategic recommendations for the company. As noted above, ISS prefers dissidents seeking board control, to
present a detailed plan for the company, which could then be compared with that of the management&#146;s current plan. In this case, the management seems to have a distinct plan, which is to diversify by introducing the new MPSC service. Although it
is difficult for ISS to ascertain the future success of management&#146;s strategy, we note the market seems to have responded positively to management&#146;s initiatives.&nbsp;For instance, Cryo-Cell&#146;s stock price is up 21.7% since
announcement of its 1Q FY2007 result on April&nbsp;16, 2007.&#148; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>&#147;. . . Further, ISS believes that management&#146;s plans regarding the
direction of the company are much more substantive than those presented by the dissident. As such, ISS recommends that shareholders vote FOR the management nominees on the WHITE proxy card.</I></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company urges shareholders to vote <B>FOR</B> the Board&#146;s nominees by signing, dating and returning the <B>WHITE </B>proxy card and to discard the gold proxy
card of the dissident group. Any shareholders requiring assistance may contact Georgeson Inc., which is providing Cryo-Cell with proxy solicitation services, at (888)&nbsp;605-7511. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="8%" SIZE="1" NOSHADE COLOR="#000000" ALIGN="left">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>*</I></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><I>Permission to use quotations was neither sought nor obtained.</I> </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About Cryo-Cell International, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Based in Oldsmar, Florida, with over 135,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a
state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL
(1-800-786-7235) or visit </FONT><FONT FACE="ARIAL" SIZE="2" COLOR="#000000">www.cryo-cell.com</FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Forward-Looking Statement </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Statements wherein the terms &#147;believes&#148;, &#147;intends&#148;, &#147;projects&#148; or &#147;expects&#148; as
used are intended to reflect &#147;forward-looking statements&#148; of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results
anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to
types of stem cells other than cord blood stem cells, given that such new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are subject to further research; the need to complete certain
developments, including completion of clinical validation and testing, before any such process can be commercialized, and the Company&#146;s development of its final business and economic model in offering any such service; any adverse effect or
limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease
in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation
of our new facility; any technological breakthrough or medical breakthrough that would render the Company&#146;s business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as
a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any
continued negative effect from adverse publicity in the past year regarding the Company&#146;s business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and
uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully
review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on
Form 8-K filed by the Company. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g81558img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g81558img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-`"M`P$1``(1`0,1`?_$`,4```$%``,!`0``````
M``````D`!@<("@,$!0$"`0`"`P$!`0$!````````````!@,$!0(!!P@)$```
M!@$!!@4!!`4*`@L````!`@,$!08'"``1$A,4%B$5%Q@)(C%!(R51,B0F&4)R
M,S3&)[>(.4EA0T1DA#4VEM9(6&B8$0`!`@0#!`4&"@<'!0`````!`@,`$00%
M(3$205%A!G&!D;$4H<$B$Q4'T3)2<H*2LB,S@^%BA"4U%D;PHE-S)#8(\4+2
M-`G_V@`,`P$``A$#$0`_`-V66LLT+!V/+/E+)L^VK=+J,>:0EI)P!E%#;SD0
M:,&#5,!7D)63>*D;M6R0&4774*0H;QVFIZ=VJ>2PP-3BC@/[;!MBO55+%&PJ
MIJ%:6DC$^8;R<@(!G#:GODB^1*:EEM)$/$::-/C*2=1*.4+8BT5FY86QP*J`
MS;J+GE'<LGNWJM(%B*3$YN4L_,<-XLZJ*S6A(%>2_5RGI&0ZL,.*CCL$)R+C
M?[ZLFU@4]"#+6K,]<CCP2,,BJ)$5^/KY+6+4)6)^3*TO+*F`+DC95*Y$KBCG
M]845#JS4R@#83;@\8Q0N[_E_=M#[6LQ.E5$D(X2GW#OBQ[#Y@2-2;@HN;CJE
MWGNAFT[Y"M66C'*<#AGY'J@QEZ=8E!0KN>JBP:E*+--1!N><5-!-6D';(:/Y
MI#/T4F<=-,$U.:H@MO*4TKEHH+DP:FSJ(<&:#W8X@[L2#O$1-7RYVFI327Y(
M+2LG$]^$@0-N`4-Q@^<;)1\S'1\Q$O6LG%2K)K)1DDQ72=,9"/?()NF3UFY1
M,=%RU=ME2J)J$$2G(8!`1`=E122DE*A)0,B(=4J2M(4D@I(F"-HCN[>1["V(
M(6Q!"V((6Q!"V((6Q!#=MUNK-"J\_=;G-Q];JE6BGLY8)Z57*VCXJ*CT#N';
MQTL;?N(DD0=P``G.;<4H"80`>VVUNK#;8*G%&0`VF(W76V6U/.D):2)DG(`0
M!=_KIUOZ\KW8*-\?E-9XTQ/77OETUG.],697IRJC^$Y<.9AE+15=5=MQ!9"+
M9,9.9!$045,@!N$K4+7;+4T';LK74$8(3^B1/22!TPEF\W>]/*9L:0W3),BX
MK]((&\``JVF4/POQ\?)6NU&4=_)G:T;*)>?Y<T2N?;H.@#>"/&2=9H]+Q>`B
M$8!=WCR_NVA]K68'2*).CJGW>>)_8?,!&HW!7K-WI2[_`#=41P.M/7C\?%YK
M=2UV5Z/S5A:QOBQD3F:EM&7FZ14^,RRK&2CV$$SF)-HW*9=6(EV+&2<(D$Z#
ME0I1WS^S;5=FE.6LENI`F4'+LQD.()`VB(/:UYL;R6KRD/4BC(.)SZB`)G]5
M0!.PF#VTJZ5;(U1KE[I$VQLE1ML0QGJ].QJO-92<5(H%<-7*)A`IR")#[CIG
M*51(X"0Y2G*(`J.-K9<+3H*7$F1&XPZ,O-OM)>9(4TH3!&T&'1MQ$D+8@B+<
MXV*8J.%,P6RO._+Y^L8MR!8H-_R4'/0S$+4Y>2C'?3NDUFR_3/6Q#\"A#IFX
M=Q@$!$-IZ5"7*EMM>*%.)!Z"0#%:L<6U2.NMF2TMJ(/$))$#&T&:HLZ9D^/#
M.6;\CW@UBRA4#YM"O688&N1HQX5+'$5.U_\`*HF*90[GH)5P=7\5`_,W\)^(
MH`&VU=:&EI[NW2LIDPK1,3)S5(XDSRA>LMQK*JQ/5CZ]52CUDC("6E((P`E@
M>$4J]_.K/^%=[BO58WK'[FNP.\.T:3O[2\EZORGR7M[R'^L?5SNFY_W<>[;3
M]E4'MWP?J_\`3^IU2F<YYSG.,GVU<_Y;\?ZS_5>(TZM*?B[I2EY(DOY.9>PZ
MJ]:6FOX_ZW*O8^J=;$W;)BD><P*%<RR,I(.'JQ./E*+5''$.\=,P.'#U,H41
M\2E$(+*E%!;7KLL3<D4IZI=ZB`>`B?F%3ERNU/9&R0U,*7+C,_W4@D<3![*1
M2JMCBH5NATB$8URI5*'905?A(U$$6<=&1Z)4&Z*90^HYQ`O$HH<3**J&,<YC
M',81577%O.%UTDN*,R>,.K++=.TEED!+21(`;`(=.W$214#73IG8ZK=-F0,8
M)1\<YNI(Y2QXOD)`Y&P1&081)1S!*$D#%-T+:6'CCW9Q`2]([4X@'PW:%KK3
M05J'YGU<Y*XI.?9F.(C+O-O%RH%T\AZZ4T$[%#+'CD>!BC5#S=EOXP]`V-TM
M4>/U;E8JUDY;%=;AJ9<X>053I<NUF;)5G;F;=(]**<*DR<1Y6^[C(@BCN'A#
M=MJ.TM/>[JOP*]*"C424D8B0.''/MC&9K*GEVRMBXHUK2YH`2H'T3,C'A(B6
MZ46(U9?)O@;2DYAZG*,K#D?+DY%1TLVQ=1RM'$K$MI9LDZC36B5=*$90AY!%
M3B00*5R^63`%"M^48IQIT%DJJ\%P$(IP9:E9&6<AM[N,7[GS#16TAI04Y5*`
M.A.8GE,[)[!B>$08A\N;2"J^$;ME;3+D;&-5S1D:QX_)+2\ZW_<WMR4K;1Q-
MSC&8KU=D'+%Q%V,'Z7)2X%4&JX$.8R9MK1Y?*G'6F'T+<:0%2`SG/`2)VB76
M(ICF<(;9=J:=QMIYPIF3\61&)!`.1GT`P8XIBF*!BB!BF`#%,40$IBB&\!`0
M\!`0V78:H;MPM4+1:E9[M9'16-?J%?F;/./#[N%K$P4>XDY!?Q$`$4FC4X@&
M_P`1#=MVVVIUQ+2,5J(`Z3A$;KJ&6E/.&2$I)/0!,P/3%'R>8@N6FBQ:J<F5
MN;PKCF.N#^E59G/R+"Q6?(4Q',FSA=M4H6&3(L^=&>+G;%3`1*51LN=0Z:21
MU`UW[)4-UHH65!QXIF98!(.\GM[(PZ;F&E=MZKE4)+-.%%(F9E1'R0,]W4=@
MBL49\J^IK+B:UBTV?'IE#(..R++)L;=,RTBT++D2.)05:^4UAY"<?A]2;:0?
M<(^`FW[738J*G]"MJT(>W`##M,^T",Y/,EPJOO*"A<<8^42<>P2["8E_`GRS
M8^N^2FN$-1>++II5RV^=M8V.C,@\XU8D9-ZIR&;!29D(NOR,$ZDG`@1J+UD1
MFN<>`CD3B4IJ]58'6F354;B7Z<"<TYRZ)D&6V1GPBU1<S,/5`HZ]I=-5$R`5
MD2=DR`1/9,2.^*Z?-)E.XW&>T^Z(<<NE$IC-5DA9RTH)',!9!!Y9FU6Q_$/@
M3,!CQ9[+U<BY3-X&&-1-]@;7.6V&VT/7-[XK22!PPFH],I`=,4>;:EUU;%G8
M^.\H$\<=*1T3F3T"#*X"PA1].F)*7A_'T>DRK]0B4&9W()$3>SLN<H*S5EF%
M"[S.9B>D3*.7!S"/U'X2[B%*4%RKJ7:RH54/&:U'L&P#@(:Z*C9H*5%*P)(2
M.T[2>).)B8MJ\6H@W4G@^LZC<(9%P]:F39TTN%<?M8MRX(4RD)9D$3N:S8F2
MH@)V[V$FTD7!#EW"($$@[RF,`VJ*J71U2*A!Q2<>(VCK$4Z^C;KZ-RE<`DM)
MEP.P]1QBGWQ9X)U(Z:\$V'$.H6/@F9(6[/)C'7DEI;V=)&OV%FV>348)VZ:8
M,&[6S$<N$DQ#Q%X<0\`VT+Y54=;5"HI"<4R5,2Q&1[.Z,KERBK[?1JI:X)$E
MS3(SP.8X8S/7#'U!?+#1J%DYU@K3OBBY:I\P,';J,E8JAF63K<5*LS`D\C22
ML=%6&2G7L8OO(\Z1D+1L<.!1R50#D++26%UUCQ58XEBG.15F1T$@">R9F=T1
M5W,K+-1X.@:74U0,B$Y`[I@$DC;(2&^(C>_+!J"P^LPF-5.@3*6+<>/GC=HM
M=861?2246*QP+O61F*]%PSAP(#]""DDS5./@4##N`;`L-)4`IH:MM;P'Q2,^
MPD^0Q5/,M=2R7<J)QM@GXP,Y=H`ZIB"'W;,..L\Z,,OY1Q796=JIEEP7E=9A
M(M>-)9!=&CSZ3V+E&*Y4W<7,1KDIDG+5<A%45"B`ANW".0U3O4MR;8?24N)=
M1A](8C>#OC<>JF*VTNU-,H*:4RN1^B<#N(VB!6_%]_I,ZE_Y^I#_``BA-MR]
M_P`?9_+^V86^7?\`;%1^;]@0.;_9#_SF?V<VV/ZF_9_/&%_1_P"U^:")8JW2
MGSSYI7E_K<P^/Y4(05A^I($<7XQCT>1Q>/A&2#D`W?R3&_X[9%1Z/*S03D5B
M?UE>>-VF]+G1[7F&S+ZB!W$QH1V4H>(6Q!"V(("K\[:A4=(-*6.`"5+/=/5,
M!@XBB"=0OYQ`Q?Y0#P^(??LR\K?Q!?\`E'[284N<OX6C_/3]E43[\>FD:`QI
MCV'U`9.CVMSU/9P8-<D7W(5@;I2$U!=V-49..J%<6<D/Y$QAHE=%!P#<"'77
M*8IC"BF@FE4N]P6\\:1DZ:)HZ4I&`,L)G?,_VG.+MCMB*=@5U0-=Q>&M2CB1
MJQ"1N`&[NE#E^4#3Q[B]'V2(.-8==<J"V#*-((F0!<JR]0;.W$I%MQ`HJ&4G
MJNN_9$(40XUED_M$`VCLE7X.XH43)M?HGH.1ZC(Q)S%0^/M3B$B;J!K3TIS'
M6)B.U\9.H3W&:/<8620?==;J6R'&-W.<V]PI.TQ!LR9R3C>83F5GJVJP?F.(
M!Q*.3?H'8O5)X.XK0!)M1U)Z#LZC,=4>\O5WC[4VXHS=0-"NE.$^L2/7$%_,
MMF.1H^EQEA^J"JXONI.Y1&,X6,:\76O()-TUD;*FW`@\8A(J=%%&``'B"3W;
M6N7*<.UQJ%_A,I*B>.0\YZHI\UU2F;<*5K\:H6$`;99GMP'7`SL<:>(K4%KJ
MQ=HOFU#RN`=#&,VC2WP:*JQ(RU7".0@Y;*3]TF10GXE_R]:`:.CAPJ&B6`I%
M$HB([;3U8JDM:[DG"KJEX':!B$_50)CB87F*%-=>6[2O&BHV_2&PJ$BL_26J
M1_5$:EX^/81+!E%13%G&1D:U;L8Z.CVR+)@P9-$BH-6;)FV(FW:M6R)"D33(
M4I"%`````-D8DJ)4HDJ,?1TI2E(2D`)`P`R$#U^3#234=4&G>RJJ,X:/REC]
MB>P8WN+[A9JLW2"R1G]9D9))!5T:O65J)T5$?J*FZ%%<I>-(-^7?O>'8_=;R
MY7\\<TNJ:Y8MU*M^I*1J5H0,`A,QJ<4J2&Q,34H))`,XK/<IU7.-0S9;8A*K
MP\X$LDX#43B%&1(1*95@92G*8@>E,TRWU74%I+U-9IR"^LIL/0-"H\O)NZXH
M5K8F]/C[)'P=AZPTHN_2D0?3J"SE59,XN#MS+&X5%!`/Q%8__H8^ZXS6\W<B
MU]D]T]XJPU3W3Q27EL^N6E+;E33AE`#1,M?JEDMI)("P,?K53_QS6EY#E!?6
M*[FN@8!=I?4E`7ZM*B0VYZPG6-FI,E$8Z9X:(`$!`!`0$!`!`0'>`@/B`@(>
M`@(;?N]*DJ2%)(*2)@C(C>(^8$$&1SC[M['D+8@BA_R59XEM/&CG+%WK3Y2,
MMTPSCJ#4I)$PD<1DS=GR4*I+-5`$#)/8:'6=NT#AXE60(/W;:EEI4U=Q;:6)
MM@ZB-X3C+K,A&-?ZU5#:G7FS)T@)2=Q5A/J$R.B(Z^*O2S5]/FEVBVP\.V'*
M.9ZY$Y!O-C73(M+"PL3<DO5ZND\.`KHQ4'".D!,B!N%1\HNL;>8_A-?:Y=77
M+1/[AM12D;,,">DGR2$5^6[:W0VY#LAXEU(4H[9'$#H`\LS!';!7X*V0<M6;
M-$1T_7IY@ZBIJ%EVB#^,E(UZD9!TR?,W)%$'+9=(XE,4Q1`0';'0M3:@M!(6
M#,$9@QO+0AU!;<`4A0D0<01&;7##9QI'U"?(]H>92#M7%UFP!E3*6,HQVY4>
M>5+)8X&:8()*JF$PN%*=8C,G2F[C<&A43G\0W[.50?:%)1W,C[]+R4J._P!*
M7>)CI,(-(#;*ZOLX)\.IA:T#=Z$Q_=,C\T1+'Q??Z3.I?^?J0_PBA-J][_C[
M/Y?VS%GEW_;%1^;]@0.;_9#_`,YG]G-MC^IOV?SQA?T?^U^:+_:S'QM'_P`L
M.`M5$R4S/&.7H>/K=OFC)&!BP4;Q"F-;>9R<H<.^$@I"%EC!^L8B)Q#>)1VR
MK</:%A=H4XOMF8'7J':9B-N[*]E\RL7)>%.Z`%'9EH5V#2J-$**R3A))=!5-
M=!=,BR*R)RJ)+)*%`Z:J2A!,11-0A@$I@$0$!WALH$2P.</0((F,HY-B"*^:
MK<R1N`-.F7\LR+\L>K4Z1-+01^(A5G5MD&IXNHQ[4IOZ1T_LCUJD0``1#BW[
MMP#M;H*9576-TX$]2A/HS/DG%&Y5::&@=J5&12@R^<<$CK,HS&YOL^<\@_$;
M5<F9YOULR#.7W5HS>5&2MKE-RX;4N!HMSK2(,!3;MP*SD+#&2"P>`@<.$P#N
M'9VI44K7,"F*5"4)13X@?**DGR`B/GM6Y6/\L)J*U:EK75>B5?)"5##I(,:Q
M<>E*2@4<A"@4A*?62E*4-Q2E+"L@*4H?<``'ALA._BJ^<>^/I;'X"/F#NAWF
M*4Y3$.4#%,`E,4P`8IBF#<)3`.\!`0'Q#:.)8`3HN*.B_P"2G4/H_>":/QMG
M1`V4,.HJB)&9'2"+ZQ1D<Q.KP%^BO+RL6<2^*BL$D7[=VS7<OWE9F;@,7FO1
M7W$]LC](PE6G]TW]^UG"G>]-'E(`ZICZ(AQ3"7O$^8.,B_\`O'%NA>HIR+T`
M$QF"^3%5D7:9!`P&2Z]"VR+4IB[MX]N'#[AVX2?9W+Q5D_5*E]'_`*?:CM7[
MUYI"<Z:C1/AK^'41]2&5H?=)47Y?M=M+L8]%-7A*ZSM<3<?0H_:K7&N79!)M
MQ>*@KUNP$<AN^U-`P_8'A+<QZWEZE<1BE,@>PCO$HALY#/--8RY@M>HCZP5W
M&?5&@K92AXB&=1,M7*_@G+=CMJYF]=K-!LMFDU2*I(*\JNQJ\TDFBHM^$"Z[
MAB0B8#^L<P%^_9`]Z?NUHO?#[OKK[L[@\JGI[Q3%@.I&HM+U)6T[IF-0;=2A
M93,:@"F8G.->P\RN\G7=CF=I(6JB47-),@I(!"DSV:DD@'83.`97#7TT:Z5\
M:Y?D*?=IC%%EOCFB1K4D4WC7I)ZM`T>V"-EI,7#MDS1(P*Y!FX1!<'Z[)5,A
M2B0PA^`K?_PL_P"4/-R;?[E/>/=K`Q[H[4^VXY54SJG:FHIT+F$,TY;0I#K@
M2$J+I0&]6HE4@%?7*OW\^[.TTSO/7+U%<%\SU84A+3B0AMMTC$K7,@I3,D:=
M6J4AO&A"GV6NW*J5JVU&2:S%6LL%%3E=E&2G-:R$+*,D7D:[0/XB*:S18A@W
M_4&_</COV_IRW2IH6TT2$Z$,I"`G<$C2!CN`E'PL/BJ'B4JU!STI[]6,^N<.
M/;N/89.2;_7<58_NF2;:]2CZU1:S,VF:=+*$2`K&&8K/E4TS'$`,X<\D$TB!
MO,HJ<I2@(B`;2LM+?>2RV)K4H`=<0U#[=,PNH=,FT))/0(R,VR]ZE]17QV:A
MLUY<O5QO-99ZD\3M*;'6)TDXCJXT8ELP6;RE-%L@)&B$E?XAB)A$P!TPEW[R
MCL_MM45'=V:9A*4++*ID;<I3^J3UQ\Q=>N%=8GZNJ6M;8J$:0<@,9RZU)'5!
M%,"?$+@+,.$L2Y3:Y^U%)$O^.ZA:EFT1<:^E&,7TQ!LG<E',43UI<Z#:-D%%
M6Y4S'.9,$^$1$0$=LBJY@JZ>I<8+3/H+(Q!G@<-L;M%RO155(U4A]_TVTG!0
ME,C$##88EK^![@O_`.0&IO\`\Z5W_P!*[5_YGJO\%CL/PQ:_E"C_`,>H^L/_
M`!B-&VA+2%IPL^;Y"E:D[==M0--TY9T(ZQ?;;Q2IB>3AI_$4PW<O)B$CX)E8
MR(-8J6072,90A"@HF80$H@`S&Z7"M0TEUE*:13R/2"5`3"QD299B*PLUKH''
ME,U"EUR&'/04I),B@Y@`'(SCSOB^_P!)G4O_`#]2'^$4)M[>_P"/L_E_;,<\
MN_[8J/S?L"!S?[(?^<S^SFVQ_4W[/YXPOZ/_`&OS1I]U@Z4J)K#PS,8IN9S1
M;XJY)RDV]LV3<R--MS-!=%A+MT5#)@\8KHN%&SYJ8Q2NF:QR<1#\"A$FWU[M
MNJ0^WB,E#>-WP'88^AW6V,W6D-,]@<TJVI5L/F(VB`Z8NU?:N/C2:LL&:R,,
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M-OY=:40H/7)0EAL^`;YG4>$93@N?-3R4J0IBTI,YG,\?UE2RD-*>)SL+\T5`
M@J#H*Q3CN@P!H^L4S*U!KM>A8MJNY!A#0]"O;%FGPHD564$J29>8J?>910PF
M,(F,(C4Y;=4[=7'G3-:FU$D[RI,7^;&$,65IAA,FT.I``V`)4(-+0`$*)20,
M`E$*C6P$!`0$!"&9`("`[A`0'9:=_%5\X]\-C'X*/FCNAW;<1+`2/F,Q[8Z:
MPP+K>QJBFE?M-V0(1O+.A14537JTQ,-G<*:5*F8HJQ#"V)$9K)[PXF\TN&_<
M([,W+KR'"[;'OPGD&72!C+C+'I2(4.:F'&4L7>G_`!J=8GT$X3X:L/I&)-^'
MS$\M7M/5GS]="J+Y$U47^>RG-2#GB%TM71DI%"ME/S`YA4GSIS(2:?B("G(E
M_0&T',+Z5U::1O\`!80$CIV^8=46.5J92*%5:]^/4K*R>$S+MQ/7#'^1C2+F
M=/+5!UW:1&BC[..,$V"-QIC%$5WUX@XA-PV9OX]@51$9YX2#>N(J2C@.5:0B
MU"%0_&0*526SW"F\.NUW#"E7D?DD]V.(.PYX&(K]:ZOQ*+S:Q.L;^,GY0&T#
M;A@1M&6(CFQY\W.E]W!IM,XP>1L)Y)C4@;6>H2-/F)UHA*HARW1(I['M_,@;
MF6*(E(_9LET]_"8HB'$/CW+-<%3I2AUDY$$##CL["8&.;[<42K$N,U`S24DX
M\)8]H!BL6H'5/F3Y3U&VF'1ICJWP6%IB6C5<L9KN\:K#0[B(8.TGJ;)X=NHY
M:1U?;.4"NCL@75EY=5%-$K=%+FBI=I*&FL?^MN*TFI`.E"3,S\YV3R&<S&?6
MW*JYC_=UI;4*0D:W%"0EGU#;*>I64@,RWN=#F%G^D*.T;23%PZQ]%U5M#M)H
M"()V%M:6RZDL&0F:PE53:V8]G75D!$.)(QE3HF`R)C$'`%SJ1<#<0?OBJ<MD
MLM/1+#],,YL](;6+4H?<!,I[9YZNF>/DR@/^.LFZT?B1<.\6Y<QC-ZA-)S>2
M=N:=?*6FZ4-5&;YRLNH,<^Y+].LD=*F,LX@9GD-R.1.=D\Y9S&487F+;?QZ^
MG6&:^6*5;?A^<,99B%9BHNW+!--5-E^V3]%2?^V>[.7%*I">1BVZ/SHZ(3QH
M.UR9@:R`)<1X,]#9*/BK@`;VP.T;*I#"?B\`,+D"?I$-L\\KW/5(>KEOU?HG
MY(U!SC:-.H^MU;M./?+RQ33*67M6_P`O$I&XBP=C.?PKI6),LGMRR!<4EDT+
M`G'N4UV[F>DD01CYLL:H0%V=>B%'?->%34=N0(F0R.DQ3V_E])J*I8=KI8)&
MSH&SBHRPR$9-157/FA0I:-M3-MGZ2E;9;SD9;$)GCB3N-0AHSQ&RTBO-'$>T
M<-L<O*(\J"LB8J2DTK,/3FDU;PY.'+2<60;4(2HF'<GU)0*`%3`"@M&XU!N'
MM$_C:YRV2RT]$L.B&T6JE%K-J2/N"C3/;//5TZO2Z8#GISU7Y6^+)9]I9UGX
M\N,AB&'F95SB?,E.C%9F&2BI%XL^7;1YEU6S26K3YXX,\*V(N66B%EU4%6RI
M.7RV*LH&+Y*NMJTBH(&M!,C/S'9/(YSA5H+G4\N3MMV;6:4$Z%I$Q(XX;P3C
M+XPF1*+1Y'^;O2\R@EFF#H7(>:LDR*)FU7J;"GS$"P7EE_PVA99[(H%E#-BK
M&`3)L&;QPH'TE*`CQ!19Y9KBJ=44-,C,S!PX;.T@1HO\WVX(E1A;U0<DA)`G
MQ)Q[`3$6:6=*>8*YAO6QK&U.1[AEGS4)AW+8,:P[:\B5JE4D*K+RSLC^,`5C
MP\A..VC-%O&@/-CXZ/024W*G433L5U?3KJ:6W41G2,N(QV$S`SVRQF=I)BM;
M;;5-TE7=;@)5K[2Y#:E)!.(V$X2&P`#.//\`C#:/$/B>U*MUV;Q!P<^H[@;K
MM7"+@_'B.$*3@053(J?C,&XNX!WCX!L7L@WYDC+[O[9CGEX$<LU`(,_O?L"!
MU>6R7\$KI?+)+JO>3S.E\O>=5RNW=W-Z;D<_E;_Y7#P[_OVV-2?YEG,2\/YX
MPM*OY0E(S\7NX1L7V^>1]4CB700=(JMW**3ANL0R:R"Z9%D54S!N,FJDH!B*
M$,'V@("`[`)!F,X\(!$CE##;XDQ4T?%DVF,L?-9(JG.+(-Z97$7Q5=^_FE=I
MQI7`*;_'BXM^_:8U#Y&DK7IZ3\,0BEI@=0;0%;](^")``````````````-P`
M`?8`!]P!M#$\?#$*<-QRE,&_?N,`&#?^G<(#X[$$?K8@AKW&[TW'<`ZM=]M5
M>I=88JM$7MAM,PP@85FJ_=),F2;F3DUVS-`[MXN1),#'`3J'`H;Q$`V[;:<>
M7ZMI)4L[`)GL$1NO-,(+KRDH;&TD`=I@$_R1ZA*OK%LN#-"&F>]Q%_?Y2R/$
M2F4['2)!.=KT%6(3>[0:N9J*4<1[T(U(7$V](F<X-R1:('$#*E+LTV:D<MR'
M;I6H*`A!"0K`DG@>H#?,PFW^N;NKC-EMZPM3C@*RDS``XC`RQ4=TAO@[]2J\
M+1ZK6J76VA(^O5*`B*U!L4]W`TB(./;QD<V#<``/):-B%W[O'=OV5G%J=<4X
MLS6HDGI.,.33:&6DM-B2$I`'0!(0.3)FLO.U9P=A')^/,65?(]NO&K/*>([5
MCMB,PWF)S%.)9/4H]L1<8@,IP+Y@?4O!B:D2U>G/'R4NJ+00;E<)JH<1)'KQ
M64XK5;A[4#ES&*6`9U&@7!5/#^1K5BH^58"T8]:X6Q?E9JXEXA>V4^6\WDU;
MFZ9'%-^S&/%(A%6PK(JIFD0\ZV)(4I(X$B(EL,.F;B$*/$`]\-5'4-GBB:",
M&9S=OL7KW[-,AI><L&F.M/-_DZU1*]J!D\=-):(A</5C*LY<\BS=:3L[P6IF
M<HQ,Y_#,=L4$E`4X*BHS423$B4I2-*0`D;HD2YY_S#3M-=?OPV9DO>+/FF@8
M[3LMGTD9NHQH*!N%\AJN\>>W&3OKG*EBDF3-RL9J="322=F.18J?*3.!_(]B
M+4M8FH%QICU:WBNQN+;OE+!N:Z]AK%LI;:#DS!]0R&^LT=A%=`^1\5VV?G<F
M8Q39SN574:*ZKE4K]@T;S#5$[1TDF<@AWX"SAAS/66<L(/,08KJ<%BW">);]
M<2V2G5Y/(V-,KS-_U&TK,F/,DOS)K1[1WCAWA=L!%$2%(NFN=ZDNX9.6BNTW
MB'P-(6O3TGX8@-+3$ZBVC5OTCX(Z.B;6C9=8]7SI7J_.X=J&0:FXI]YQ4\JC
M%YD*LQ6`LUPSBPX2?9`KC2\0KASDJ'1@IB&L\:VDHQ%O*1HF3*BDJ0@PDSQ.
M<3@`8#*.:NZDM1-=T.Y1U17Z<Q'<[?"Q]N>U"O5C&=JHE;C34K(-BHSE.>&0
MRS>I.P%F4XI)T44%8X6IA.3\8!`Q2")4R=9\[97S9D/!6();#%+K^*<98\NU
MKE,OXSG<M'OEJRA)Y`;U>KM*U&7['S2O4B&88]74DI,RK]X]<O"H-4VW1K*+
M^I4I)FDD'A'*DI6-*P"G<<8JT^U=*8[QSHSU"T'3IC"(H&6J?:LC:I6-;A"E
MO&-\7U>OU]M;[MBU]7X]@6YQV.+/9DY>107:&<2E/8O%F:17H((*]K>><$EJ
M4H<23'"&&&SJ;0A*N``[HF:0UNR#+1C<M0ZS_$K*VR.:LOX*PX^F9I5CB2:L
M;74[>-/6$['99H\V"SBG.V45'3M@=,WB0*1J;U=J*1`3`D<2QW(C6H_M>FC2
MSF^F,J5)R&9L]X<P7D)HU5=2-;@YZ>R@KB3,*-5=L)3B<C7;9#R*44X56<(K
M)))JG*J4WB001+E)\/!RR<&_?P\!>'?^GAW;M^Q."0C][$$+8@A;$$+8@A;$
M$+8@BLNK_P!N'H#<_=CTGH9SJ]W5UO=')ZSN&,[;X>S?WAZCN+I>7R/#CW<?
MT<6UVW^,\6GP'_M8RRW8YX93C/NG@/!+]I2\'AJG/>)?%QSE%2]!?\+_`+IG
M_9=V/ZC>3*^;]5WGZ@]N=0EU/EGJ3^=^1=1RNI\N_`XN7SO'@VOW7VWZL>TM
M7J9X9:9_1PGT]49EE_EWUBO9.CU\L?C:I<-6,M\NN"G;8<,<5%AO:MY%@?RG
MI_)?<ID_T2W=Y[O<-PZ@O4CE<_\`:.=P]]\7F'Y7^MR/^A[$$>#IQ]EGISJ;
M]M7:_ICZ]Y]]P_:'<W;OKKPM?7[INJ_"ZOK?Z]Y'^7=?SN1^-S=B".CD/VG>
MSO#_`)CWM[<O+M.?H;Z6>LWJ!N\PIGM\[(]./[X?.^L\IY/#^U<._J_HYVQ!
M#AIOH5Z74KSKUQ[9];J?V?[BO<!ZA>JG<47V3N]8_P"\#R7N#D=)U'Y/OX_Y
M',V(([%R]K'1ZD>[]W0>K.'?<#S.]NF]4^W<)^E?]3\.I[>[,XO*OV3AY?5?
M5U&Q!$:6+V!^I.O[KNV_4KT8Q/[_`/MOO?S+TI[1R7Z;=^=L_LOF7I[Y]SO+
M?SKR3I^L_9N@V((L:CZ%>X2L^7^7>NGH18?)/)O-^3Z'=[4_JO,/+?W2Z#O'
MH_*>K_;/Z]T'X/F&Q!$:R/M,]HEJZ_I_:KT-U[FW][<CHN_IGO#?R_WS_P#'
M/5[^3]6_^B_!X=B"(YU:>T7U%BO5OUG]5?3%_P!P>W+W)=Z^@7GCKK_5OVU_
MFGI7W!UG0>=>/5^8>5?B>8;$$3]`>V_J=.W:/:?1^EUC]NO:_4=H>DW;5*\W
M[:\H_=;MGM7R;IN=]'2\'3^''L017'3S_#Q])M)?MV[9]$?73-WM/[:[Y]/?
M67BU!^IG;G7_`)5T_!WYY-UWY3RM_DWT=!L01Q9<]C7IOE'N7O/MCWC53N7T
MG]<^[_>'UM!\B].O2W]\.Y//O+.J[=_+/->LZG]IZ_8@B7/[M?;1_P"\7L;S
:;_[9>Y?J.Z?_`-$>4^8?]E\J_P"I[$$?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g81558img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g81558img2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+@"O`P$1``(1`0,1`?_$`'0```$$`@,!````````
M```````'"`D*`@8!`P4$`0$`````````````````````$```!@(!`P(%`P(&
M`P`````"`P0%!@<!"`D`$A,14B&1TA05,2(*43)!@;%R(Q<S-!81`0``````
M``````````````#_V@`,`P$``A$#$0`_`+9O(OR15_H/&:VCQ$;77+M#L=-V
MVJ]6=:HTY$-\GM6P'MP1-*=6ZN)I2H,2KJ/*W(@;N\FDF`3@&$!8##1X#T&]
MQG6^_)S&VMYV0VLM%)9"T@*UYC.M#@VT_4L/5JP!..CD5":QOD]E2!G-'DD+
MD^.AZA;V>7P)L"P0`&%\A=J<D.B+/1<PH"QXG?6O,PV-H.H;E<;J@J1UO2EH
MC9=GQ:''2QBE<0412*36.N8W;+:H.=V8;DV*%A!V#E(,BR0$[(ACP(6,"SZ8
M%G&/\L]!CY!^[/0'D'[L]`>0?NST!Y!^[/0'D'[L]`>0?NST!Y!^[/0'D'[L
M]`>0?NST!Y!^[/0'D'[L]`>0?NST!Y!^[/0'D'[L]`>0?NST!Y!^[/0'D'[L
M]!F`8\]WJ+/]@L_YXQ\.@H)4G;SQO'_,7DJJ;JSG:'ZBBNROZM8E0S#F^-):
M0KM\B8U#>D.&(A.J<+%>W!T,,`$(LG'XSZ^H`YP%^?H-2G4$B5EQ9RA4Y94T
MAB[N:UGN#2K$:`D]0R.Z!_:#^\@99Q9[>\M:=24((L"":4'..@VA0H(2D'JU
M9Y*9,F)-4JE*DTLA.G3D@$:>H/.-$`HDDDL.1#$+.`A#C.<YQCH(_:MW_9=F
MTLXDFFE0RW9>L(!*'B$+KE;)1#*\K&:S&.#\$D8*A?)FXIE=D885N,I3W0A,
MG8!*PB**7F9`/(`WS3;>^@=XX]8*ZGW1\:IM34X=*QO.G)\U!C5K4S8C*L6(
M'",3F-A5+B"\&*FX_"1>B4*VU>$D>4YX\@'@(=4LW>K4F_GK5"G65\V!V/B,
M91S&R*_KY8RI&6FXTZC"!A<+CL%_7(8M!UTFSD66UI\BM\6E`$<6BR0')N`^
M/&\D#A-SUIKULA%'W6VU+MRZ$4B.:.K`_5E<+TR@2FNL,@MH1U8>R9L)$0K`
M;AB=2FMQ5DC"-&6IQW=H);R'\H%4<9,!%;VQM276LI\<HC<)16+7B"`R-"OE
M4G;G%R0M1+`NGC+*",$%M*@LTXY&63@POT"(6!!SD$RV@YD*1U=H9OVO?J<O
M&<:N)Y!`XS-[FAR.!EM\0=Y^-O3I4B&,R*:,LFGN8TY.($+P:R)U:9(O`80`
MTX9)^"P6R].3'7:HT>K+1$5#K>5N[P!93]3*8KH;>3++59GIE2R/,W<%TA4M
MC/`JWC["L`K=7EU,)+2E8&$LLXX&2N@U/93D7<-%X[%;&W6HT==4S,)"WPA-
M:M0V$"XVB(6"_)U9T2BECL[C$*Y>(VCEJM$-"D>DX%[00O&6!:<D*,"=T'B:
MS\ETEM.W-O:NV6U*L72MHU&BT:G[[<EF3:,RFD)?`9,W*'M,_--I,J%MAN%"
M)A)PL5%(UCFF(+\@1*?(4(.04."[^.-V5$JV,UTU>N2YM?1(WEYB<\3N4'@<
MDMR,,0E.%4LIVM9P^-,FDS`YA1F":C'/\(8\`P$:0!@#"A#!:]4-T];]UJ$;
M-E-?;%;Y-5:O#J0].#J4;''>"/,>*P=)XS83([_;K8A(8R#/<L(58#@!60G`
M$,@8#!!H#=N9(YI7.+SI[62V;>H=0U*Y+'9G''J"-$RL:'(PFG!F%75;)'UL
MD$H97I$2)4T@5G-BUW39+,2D#P<3Y`6C7+96LMH-=Z\V@KTYY9ZKLJ)J)JR*
M9ZWE1-Y:X^C5."56JE#>I5GE,)B/+8:,\)IV?``/J/./3/H"%53O4V[.,[Q-
M]0:CE>P=0L\C>XHGNL,EBM;UM.GJ,KSVF1@J5PF"H#Q8;0SNZ4Y&)W(1)V10
MJ),`G6'8`(6`4+7_`'-IS8>6VQ5$>-?(=L!0RM&AN;7FP$B)AM:""=4A:U@>
M1-Q+@O9I-"94E/+-:I`T+%S.L+-!C!X3.XL(-!D?,EKE7.[D%T"N>O+GIR]9
M_`W*S6U;+4%?KJZ:8*V,4QD!S](9E&)\]D-I0D4%<,>/PC,"8$L(L8\@>@62
M^-]W.A*6EVS+WJ=L'(M>X"SF2Z72YEQ7B&>H:]1A`>[6$DIV13%GFRB.M+?D
M2TX@\"5V"B`(W*/':(.`5R';P:SS[3=PWXA=BD2;6!LIJ;7FY3QI:W-2J0P.
MNF!ZD,YRJCF$V'PF0QA-'5I*IMR3]V!6F&3V9'Z8R%,JC:;?=&_YB4F3SU$>
MTP[;T5YV#4T@5`&4W2A'=<`?)<).W*S0!(4*VRP61P:CBP"R,)Q&/7'[PXR%
M^07=VBP'.,#[18#D6,Y#@?IGMR(.,AR(.!?KCUQG./\`''05\N:?DVW%XC-9
MH=L6B9M:+R#+[D:*K#$UL#LV#_C4[Q&I7(RGG\NGM=_^]/3XC6"1$^`H(O-D
M>!8[>W(-ZYO]L=I8UP`6%?"M_@[1)]G8-K>T]]3QN514V`P6_B&)RL!D4.KW
M,Y2J=!K&EP&S%K"L(<^!2/.2^\8>T'(\&,6V;C/$AH<CK!7K2W0Q=1[9)6TA
M_CUF'OPU4J>WJ1NZAZ4,\C2-RAU4.KF<,\1180>3.<8QZ8Z#1-=N*_8303<W
MD>Y2#MBH=82O8VH[OG#OKO"ZSD3&SE3XDX%CPT:9]>)F]#>2V-P9U20K!B(!
MQH7$ST$'U%@0,6_AP25]MB@.0/82PGI5++@N#;I`Y6'+W4[*IZ?508&DDH#U
MJHT0U`BA/$P<#"P9SV`[\A#C&,>F`<1_+\;4Q'%5%I^D/.;)I6>VE,26"2)O
M/&B>H\^G-TS09<&9Q($6L0K"B#LC"82,(PC+"+&?4.,X!C'/]<,\V!_C/Z-W
M;:)1I=BV>_:G3&:&GE"(.<9$[5;+CG)Z&2+&/'E^/]5OIC&`XP?\/AZ=!8Z9
MN/S5';SC+U4U0V#K/_[BD6>F-=Y*ABZ:2RF)J2I)&H`T*4+UEZBCPSO`UB@]
MS5"4]QX@*!*3,F8$+/K@(>-UJ!)U+YU>,/;2(,9S[JQ3&MBO7B8U]73:\3=_
MU3@3;&;&A,,LN3PA@(?)*QTT<*8)2#'XPG)!1J!3Y1Y$'&1`X3GT7%<ANB)6
MC^DXD&R-Z[#6_30&E%7*@,@BM<P^+2])+I'9EJS5"$Z-5Y$&=*T@($<X*"5!
MYRH($Y)P\"#@(^/Y5$LMO4OAMTOU)99>XNK;*I+6%+W',DAJL@<S;*5J@*XE
MM5G9%@[\7)Y8RIW`91N>XT*`(1^N.[&0L<ZJQ7;:(:PZX1:&K=5&^)QVAJC9
MHTB%&+8[DS&WP!@2MI)GVLI+3#&%(6'NR`(0B%ZYQC'KT$<7''P86?HW4?)#
M4,DVO:+%C.^\=DY#8UQBO7B$MU32^61^P8^ZR)+E;+Y$:ZA/0S%(0+!>$Q@B
M6TO`LYSV]H0X51RA\W'!K!(GKKOSQ_.6R.K-$MC;7T,V&K,#LF^RK*)I`-<<
M&&SHNW2J#KVYM8TQ($I4@;V9S"2`!:DP)F,BR"X<O_*+3E]_QTW&WN.8UW@-
M86]=T:UYM*+$-@8U*:A3295(Y[9T`?T*%0M3-HY6Y%DDF*$B@Q$O;GC/B,[3
M^W`6..'N,,D.XL./U@CQ!29K(U1IQP``G`<`-7/L10/KNL%V?M$>O=W(\\T7
MZC,,%G/QST%:_E8LN::V?RF>+Z>TX<N22*[JQIRJ;5:FH6<`FD#FUN6'7KZ@
M?DQ7_O)$D>,*5E^3&?"<V$FA]!%!S@.O?V%,D^_E[<>L<D10U;)BBH6^+&[N
MS]LYF11JOV3MB%R*_P#&L;!N[0G&>0/`BS@`[!XR'.<=!:AY)<^O'KO+G/IG
MUU,V!SG^GQJ^3>OP_IT%73A]..-_B,[O@--,,`FUOY12$X1BR()!(JFL50(H
MK&?@`L2@\8\XQ\.X><_KGH+(G(IQT03>Z/5C*$$F4TYM-K3.VZV-5]CF)M+<
MGRL+`95Z)T+;'UK$<DQ+:UE*AL))>F<PXO!Y00F%#+-`$604Z'[!7U&XT@;M
M@]5K&+L="1A(]/&O9D>M>JI6M3`"4:^PY8MD4=F["VO!P1'%H7QK2J$6!X*&
M<?@/G&$+?*;QD;F<YAD(KV=/+3H7J73BYZF<-99B0U6S?=Q6JXLZQE9Y1,HC
M!Y27"*XA4=:U)J=*D$_.+J,2U0::27GQ`+"7FS]"*]V$XYT?'M?"L+Y%ENNE
M>TI(93'T^"5"*2U_%8^V,M@Q4EQ"8),N9)5'4[HB`=Z_$H)9GJ'(L9!GW&-`
M=M.-_62+Z0;$4S*[SC5#+'^.T9L1KP*,21DL2K'!\<7^.MLX@4CD\;F=>3>-
M?E1HC2Q$KVLX@LL1:T60C]0DKK@BXIS8#U9-C-3C6E>@B8X?`Z1<G=H>79Q&
MY.)#D_6+:`6!4Z1Q,^JDR0AO:FI,L7!0(Q*AGG".5>).$5&F/'G->)+97:U^
MUUACA;^CVVTC;+6_ZMARIF3VYK;;38)T*<F^/L<F=6)GL"IY&@>/$FPE7%/#
M5A&03E,I+#D_H/JY%M';/YC5>O5%V#%9;KSI%6-JHKLO-3-U3"DN.]GF.-S@
MTQ2K(-$8Z[2'$,BHBGA6<[/CLJ(5?\I04:,8R\FX!(OY`6A>S>^FC\8TFTXH
M!'X8'9=3RB-2%YL"MH17".%P:*2!BQ&6=&YR,,E3*&4IS3)B2S$!9.0$BR`>
M0XQZA,]J@.PV.DJY@5H52_58[U;5];0M:>^2>!R!N?UT:A[>S/:UG50V2OW@
M;D2MK%GR+<)1&%F!%@/]W:%+R><X&XVBV^^^6=?=:8AR"4KM!M(ZN=*7+%W:
M8%F.>*OKB-,$BKB(RF.L#T5.H73#<W91K#$A)C2RKP+1X69PH'T"AU/_`"O]
MWGUC4VQ)>&BPWC75@,.5SVSJD<[0<&EE:$9@P.KL1)5M4&PM4!N`6,1@CEA)
M`>W/><6'U%@)\-IZ"U>_D/<6$>#"9>K:(7<[0U6U1%E*F<LU_JVTXT-T:2@2
M-APIP(1K2XB<6)^0EGX\A!A_A-[L$F]`L.F%@[9T+KC5-`;7ZQV+*+>I>%Q^
MK/\`LN@E\&L"JKB980W)HW&IXT.#U+8?(88XO[,@(-<&]\;T.4JO)F0&F%9"
M+H-EV#J3;RZ]4=RTD?>BH%?%U58YQ77*MRYF4&/TP[-#.N+AKJ^R]N*$WF3=
M\E*[+B^*T>#TB<@A,C(&HPGR<>'MU[?&U2"FF^);.:5S&57T7$<L,K;Z7D-:
MSJA+6?@MGXU8X,TOETFB2N)QB6JN\Q0DD;2E,;R3A`SA4$.!&!'-I7P.UG7_
M`!;W[HAM`6Q.+IM]8,XN:TTU<F9.8*;F4E5MBJO&:K7)Q2$?>GTV1'VWP+AI
MR2EJL@['B^V'@&0=AH!%ME-!-6JUT[O6IYK>@-?FX^N:IO.A$\<?62S:J:EB
MD<`.ED2D\OC\EKJ<,4?/(;%Z4X*MK&-)@XA<,)F0@!(ZPXT99=/*%(.6G;YC
M;F245U!FVK=--;T;LVR=95\:9T#PG567:$D0FG1I59TC62%S-1-C8<I0,H%^
M,C6*%!8!%`R:_M#M[;1YZ]6^4./ZRJT]"4E4J6!2F-N=O4R19:YU(CUMM(U3
M*RE34]G4H?N)VB%C)J\D8@`-SG`<A#@03A;O--QV[IU<M35K2$DDL_ONA+3K
MPAE-F-;,:>OY),X*X,;25+W=XE:5O5(RW-UP$XUJ$X8`$D8L8SC(,B"$SCKX
M[-W-=>#?:3C*M&CD[5=UGT/O''(=*VZSZR>JW<)7>E=2B/UY'E+H@DQCVWG+
MW5[*+4*#D(4B4(1#&;@/IT%ID?\`>+_<+_7/08]`=`=`=`=`=`=`=!!-SL6G
M."JVU0T]A\ED4#8]\=D2*<N>=Q%2<@EC;K["X5(;1N")Q%R3]JAND]D1F,B9
M2#2Q!,^W4GA#\1=!%'Q'ZJP/<ZU$KE93,P-=31O6?7N^IC3L=-"@895%;[<)
MR[ZNZJM2%-DLYNU&ULK*!%GNS$ER6EGE@+U3@^Y6^'PY"VC<$SJVA*$L29S@
MEAC%05G7#\N>VHEN1I6)/&&MF/(!'&QB2D@2GB<@9`@1-Y!61*3CBTY18AC"
M#(1]\'>K4UU`XSM>ZFL=B/B,W=<SZV'Z"J?3"BOL7#/I%8C-`U9>,YPG<8E'
M7Y&B6$_H2L*-+^/;Z]!+1T!T!T!T!T!T!T!T&8/U%_L%_IT'(L8[A?N#_=GW
M?U_V]!CVX]X?D/Z>@.W'O#\A_3T!VX]X?D/Z>@.W'O#\A_3T!VX]X?D/Z>@.
MW'O#\A_3T!VX]X?D/Z>@.W'O#\A_3T$4W+C!-;;(I:DX?=MXO.NELNFSE69T
MJM^'0F2V-.(KMLD,=%5>B983&(](5DB87%M*7II`0M*(:,LAJC*Q2F+Q@X(5
MU]/*B>3[MK[&N&T55()B<W3@-8N%#,NW"IG_`.LDMCNQ$Q50F$..M(95&=67
M2U0.9[*B=Y;)J_)<1J0QY=@CNP$+/8X$RQ1RJ1;O#>ZJV7]7,FDBL6QYK]=`
MZ$:+,P,(XNH<B$38KCCC8.5X<A8#I2YAR)<+'XQ(!9VYZ"0?(?CGU&'U]?CZ
MX'Z^O^/K^W]>@X[<>\/R']/0';CWA^0_IZ#SOO%'Y?\`&_BG#[/\=E=_]!Y&
MK\/A3]S@C\/X?R?Y_P#)9*SY^[['[/Q?#S^3_CZ#T>W'O#\A_3T!VX]X?D/Z
K>@.W'O#\A_3T!VX]X?D/Z>@.W'O#\A_3T&8,8_=^X.?V"]W]/U^(>@__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
